Abpro Holdings (ABPO) Non Operating Investment Income (2022)
Abpro Holdings' (ABPO) quarterly Non Operating Investment Income came in at -$362500.0 in Q4 2022, down 925.44% on a QoQ basis from $43916.0 in Q3 2022.
Abpro Holdings (ABPO) Non Operating Investment Income (2022) Analysis & Trends
Abpro Holdings (ABPO) has 1 years of Non Operating Investment Income data on file, last reported at -$362500.0 in Q4 2022.
- Quarterly Non Operating Investment Income changed N/A year-over-year to -$362500.0 in Q4 2022, while the trailing twelve-month figure through Sep 2023 was -$362500.0 (changed N/A YoY) and the FY2022 annual result came in at -$362500.0, changed N/A from the prior year.
- Non Operating Investment Income declined to -$362500.0 in Q4 2022, from $43916.0 in the prior quarter.
- In the past five years, Non Operating Investment Income ranged from a high of $247770.0 in Q2 2022 to a low of -$362500.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Abpro Holdings | 1.14 Mn | 1.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -362,500.00 |
| Dec 31, 2022 | -362,500.00 |
| Sep 30, 2022 | 43,916.00 |
| Sep 30, 2022 | 43,916.00 |
| Jun 30, 2022 | 247,770.00 |
| Jun 30, 2022 | 247,770.00 |
| Mar 31, 2022 | -291,686.00 |
| Mar 31, 2022 | -291,686.00 |